French drugmaker Sanofi is looking for one or two partners to allow itto double its size and to meet medium- and long-term development costs, according to a source close to the company. Both Sanofi and Elf Aquitaine, which owns 55% of Sanofi, declined to comment.
Sanofi is aiming for a 2.5% share of the world drug market and a market capitalization of about 100 billion French francs ($17.99 billion), while retaining control of strategy under its current chairman, Jean-Francois Dehecq, the source to Reuters. Any merger could be done in two stages, with one in Europe and another in the USA, he went on to say. Sanofi now ranks 23rd among drug companies with a 1.5% world market share, Reuters notes.
Elf has said it wants to cut its holding in Sanofi to 20%-10% to let the company find partners to speed development and increase profitability. Sanofi's current capitalization is about 56 billion francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze